Scarica l'app Stockscreener
0.392
2.51%
-0.0101
Dopo l'orario di chiusura:
.40
0.008
+2.04%
Precedente Chiudi:
$0.4021
Aprire:
$0.415
Volume 24 ore:
304.97K
Relative Volume:
0.81
Capitalizzazione di mercato:
$3.18M
Reddito:
$5.66M
Utile/perdita netta:
$-15.88M
Rapporto P/E:
-0.0346
EPS:
-11.3134
Flusso di cassa netto:
$-10.93M
1 W Prestazione:
-20.00%
1M Prestazione:
-44.29%
6M Prestazione:
-63.36%
1 anno Prestazione:
-94.39%
Intervallo 1D:
$0.385
$0.42
Intervallo di 1 settimana:
$0.3252
$0.4998
Portata 52W:
$0.3252
$13.50
Bioaffinity Technologies Inc Stock (BIAF) Company Profile
Nome
Bioaffinity Technologies Inc
Settore
Industria
Telefono
210-698-5334
Indirizzo
3300 NACOGDOCHES ROAD, SAN ANTONIO
Compare BIAF vs TMO, DHR, NTRA, IDXX, A
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BIAF
Bioaffinity Technologies Inc
|
0.392 | 3.26M | 5.66M | -15.88M | -10.93M | -11.31 |
TMO
Thermo Fisher Scientific Inc
|
585.51 | 217.52B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
202.63 | 142.32B | 24.78B | 3.68B | 5.29B | 5.1743 |
NTRA
Natera Inc
|
314.18 | 44.67B | 2.50B | -226.32M | 71.51M | -1.6412 |
IDXX
Idexx Laboratories Inc
|
546.09 | 43.41B | 4.45B | 1.10B | 1.06B | 13.59 |
A
Agilent Technologies Inc
|
148.45 | 41.95B | 7.23B | 1.41B | 1.09B | 4.979 |
Bioaffinity Technologies Inc Borsa (BIAF) Ultime notizie
Enterprise value to revenue forward of bioAffinity Technologies, Inc. – NASDAQ:BIAF - TradingView
BioAffinity Technologies Closes $4 Million Private Placement - Moomoo
bioAffinity Technologies closes $4M private placement - Investing.com
bioAffinity Technologies closes $4 million private placement of pre-funded warrants priced at $0.47 - Bitget
WallachBeth Capital Announces Closing of bioAffinity Technologies $4M Private Placement Offering Priced At-the-Market Under Nasdaq Rules - PR Newswire
bioAffinity Technologies closes $4M private placement By Investing.com - Investing.com Nigeria
bioAffinity Technologies Announces Closing of $4M Private Placement Offering Priced At-the-Market Under Nasdaq Rules - Yahoo Finance
bioAffinity Technologies prices $4M private placement offering - Investing.com
WallachBeth Capital Announces bioAffinity Technologies Pricing of $4M Private Placement Offering Priced At-the-Market Under Nasdaq Rules - Barchart.com
bioAffinity Technologies Announces Pricing of $4M Private Placement Offering Priced At-the-Market Under Nasdaq Rules - Business Wire
bioAffinity Technologies to Add Mexican Patent to its CyPath Lung Technology IP - Medical Product Outsourcing
bioAffinity Technologies Inc (BIAF) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Enterprise value to EBITDA forward of bioAffinity Technologies, Inc. – NASDAQ:BIAFW - TradingView
Form 8K bioAffinity Technologies Inc For: 7 August By Investing.com - Investing.com Nigeria
bioAffinity Technologies earnings beat by $1.46, revenue fell short of estimates - Investing.com Canada
BioAffinity Technologies, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
bioAffinity Technologies, Inc. Q2 2026: Revenue $1.51M, EPS $(0.64) — 10-Q Summary - TradingView
BIAF: Strong CyPath® Lung growth drives Q2 2026, but liquidity concerns persist amid ongoing losses - TradingView
Price to sales forward of bioAffinity Technologies, Inc. – NASDAQ:BIAFW - TradingView
BIAF: Q2 2026 saw 216% CyPath Lung test growth and 19% revenue increase, with improved net loss - TradingView
bioAffinity Technologies reports Q2 2026 revenue $1.51M, net loss $3.37M, cash $2.43M - TradingView
Price to earnings forward of bioAffinity Technologies, Inc. – NASDAQ:BIAFW - TradingView
Press Release: BioAffinity Technologies Reports Second Quarter 2026 Results and Continued Strong Commercial Momentum for CyPath(R) Lung - Moomoo
bioAffinity Technologies Inc (BIAF) Stock News Today - TradingKey
bioAffinity Technologies Reports Second Quarter 2026 Results and Continued Strong Commercial Momentum for CyPath® Lung - Yahoo Finance
bioAffinity Technologies Faces Nasdaq Delisting Risk After Notice - The Globe and Mail
bioAffinity Technologies and Pictor Apply Flow Cytometry, Proteomic Analysis to Gauge Lung Health - Photonics Spectra
bioAffinity Technologies Inc (BIAF) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
bioAffinity Technologies Publishes New Clinical Framework Addressing Growing Market for Pulmonary Nodule Risk Stratification and Early Lung Cancer Detection Using CyPath® Lung - BioSpace
bioAffinity Technologies Inc (BIAF) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
bioAffinity Technologies Inc (BIAF) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
bioAffinity, Pictor Collaborate on Asthma and COPD Tests - respiratory-therapy.com
bioAffinity Technologies Highlights CyPath Lung Clinical Framework - TipRanks
bioAffinity Technologies publishes clinical framework to integrate CyPath® Lung into nodule evaluation - TradingView
bioAffinity Technologies, Inc. Revenue Breakdown – BOATS:BIAFW - TradingView
bioAffinity Technologies, Inc. Revenue Breakdown – BOATS:BIAF - TradingView
bioAffinity Technologies Inc (BIAF) Balance Sheet - TradingKey
bioAffinity Technologies Inc (BIAF) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
BIAF Q3 2025 Earnings: EPS Misses Estimates; No Revenue ReportedEPS Estimate Trend - po-news-eg.net
bioAffinity Technologies, Inc. (BIAF) stock price, news, quote and history - Yahoo Finance UK
Top QumulusAI (QMLS) Competitors 2026 - MarketBeat
bioAffinity Technologies Q3 2025 Earnings: EPS Misses Estimates Amid Ongoing Research FocusSaaS Earnings Trends - dars.gov.et
bioAffinity Technologies and Pictor®, Inc. Partner to Develop and Commercialize bioAffinity's Diagnostics for Asthma and COPD | Newswise - Newswise
bioAffinity Technologies Inc (BIAF) Income Statement - TradingKey
bioAffinity Technologies Inc (BIAF) Cash Flow - TradingKey
BIAF Stock Gains As CyPath Sales Surge 146% In Q1 - Stocktwits
BIAF|bioAffinity Technologies Inc|Price:0.663|Chg%:-0.005 - TradingKey
bioAffinity Technologies Inc (BIAF) Valuation: PE, PB & Fair Value Analysis - TradingKey
BIAF vs. BDSX: Which Cancer Diagnostics Stock Is the Better Buy Now? - The Globe and Mail
What's Driving bioAffinity Technologies' Recent Surge - Kavout | AI
BioAffinity Technologies and Pictor, Inc. Partner to Develop and Commercialize bioAffinity's Diagnostics for Asthma and COPD - marketscreener.com
Bioaffinity Technologies Inc Azioni (BIAF) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.64%
0.11%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):